URGN (STOCKS)
UroGen Pharma Ltd. Ordinary Shares
$21.140000
-0.530000 (-2.45%)
Prev close: $21.670000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Elizabeth Barrett
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,005.08M
- Employees
- 253
- P/E (TTM)
- -6.11
- P/B (TTM)
- -8.57
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $96.52M |
| Benefits Costs and Expenses | $198.73M |
| Cost Of Revenue | $11.63M |
| Costs And Expenses | $198.73M |
| Gross Profit | $84.89M |
| Nonoperating Income/Loss | -$727.00K |
| Operating Expenses | $218.29M |
| Selling, General, and Administrative Expenses | $150.61M |
| Research and Development | $67.69M |
| Operating Income/Loss | -$133.41M |
| Income/Loss From Continuing Operations After Tax | -$164.64M |
| Income/Loss From Continuing Operations Before Tax | -$102.21M |
| Income Tax Expense/Benefit | $3.00M |
| Net Income/Loss | -$164.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$164.64M |
| Net Income/Loss Available To Common Stockholders, Basic | -$164.64M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.46 |
| Basic Average Shares | 94,773,125 |
| Assets | $185.05M |
| Current Assets | $168.55M |
| Cash | $127.40M |
| Inventory | $8.34M |
| Other Current Assets | $32.81M |
| Noncurrent Assets | $16.50M |
| Fixed Assets | $695.00K |
| Other Non-current Assets | $15.81M |
| Liabilities | $300.45M |
| Current Liabilities | $42.24M |
| Accounts Payable | $10.28M |
| Wages | $11.11M |
| Other Current Liabilities | $20.85M |
| Noncurrent Liabilities | $258.21M |
| Equity | -$115.41M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$115.41M |
| Liabilities And Equity | $185.05M |
| Net Cash Flow From Operating Activities | -$137.74M |
| Net Cash Flow From Operating Activities, Continuing | -$137.74M |
| Net Cash Flow From Investing Activities | $94.46M |
| Net Cash Flow From Investing Activities, Continuing | $94.46M |
| Net Cash Flow From Financing Activities | $8.67M |
| Net Cash Flow From Financing Activities, Continuing | $8.67M |
| Net Cash Flow | -$34.60M |
| Net Cash Flow, Continuing | -$34.60M |
| Comprehensive Income/Loss | -$164.68M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$164.68M |
| Other Comprehensive Income/Loss | -$127.16M |
| Other Comprehensive Income/Loss Attributable To Parent | -$213.00K |